A role for altered phagosome maturation in the long-term persistence of Helicobacter pylori infection

American Journal of Physiology. Gastrointestinal and Liver Physiology
Glenn N BorlaceDoug A Brooks

Abstract

The vigorous host immune response that is mounted against Helicobacter pylori is unable to eliminate this pathogenic bacterium from its niche in the human gastric mucosa. This results in chronic inflammation, which can develop into gastric or duodenal ulcers in 10% of infected individuals and gastric cancer in 1% of infections. The determinants for these more severe pathologies include host (e.g., high IL-1β expression polymorphisms), bacterial [e.g., cytotoxicity-associated gene (cag) pathogenicity island], and environmental (e.g., dietary nitrites) factors. However, it is the failure of host immune effector cells to eliminate H. pylori that underlies its persistence and the subsequent H. pylori-associated disease. Here we discuss the mechanisms used by H. pylori to survive the host immune response and, in particular, the role played by altered phagosome maturation.

References

Jul 12, 1975·Lancet·P CorreaM Archer
Jan 1, 1991·Scandinavian Journal of Gastroenterology. Supplement·H L MobleyP A Foxal
Apr 1, 1990·The Journal of Infectious Diseases·M J Blaser
Feb 1, 1990·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·L P Andersen, S Holck
Jul 1, 1990·The Journal of Infectious Diseases·M F Tosi, S J Czinn
Aug 1, 1986·Journal of Clinical Pathology·J I WyattR V Heatley
Jun 1, 1995·Infection and Immunity·D J EvansP R Kvietys
Jul 1, 1994·The Journal of Clinical Investigation·M J Blaser, J Parsonnet
Jul 1, 1994·Journal of Clinical Pathology·H RautelinD Danielsson
Jan 1, 1993·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·L P AndersenH Nielsen
Jan 1, 1996·Scandinavian Journal of Gastroenterology. Supplement·J E Crabtree
Jun 1, 1996·Scandinavian Journal of Gastroenterology·J ValleM Siurala
Oct 25, 1996·Annals of the New York Academy of Sciences·K A BirknessF D Quinn
Jul 1, 1997·Gastroenterology·E M El-OmarK E McColl
Oct 23, 1997·Clinical Microbiology Reviews·B E DunnM J Blaser
May 30, 1998·British Medical Bulletin·K Bodger, J E Crabtree
Oct 21, 1998·The Journal of Infectious Diseases·P R HarrisP D Smith
Oct 21, 1998·The Journal of Infectious Diseases·E RokitaA M Hirschl
May 21, 1999·Science·A CovacciR Rappuoli
Aug 12, 1999·Clinical and Experimental Immunology·J BauditzS Schreiber
Sep 1, 2000·FEMS Immunology and Medical Microbiology·A M PetersenK A Krogfelt
Oct 18, 2000·Infection and Immunity·F MeyerS P James
Oct 25, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·F LuzzaF Pallone

❮ Previous
Next ❯

Citations

Jan 29, 2016·Helicobacter·Aparna SinghMing Yan
Mar 22, 2013·Biochemical Society Transactions·Leanne M Smith, Robin C May
Nov 9, 2017·Frontiers in Immunology·Eileen Uribe-Querol, Carlos Rosales
Jul 31, 2013·Infection and Immunity·Barbara KronsteinerRaquel Hontecillas

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.